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Cancer is one of the leading causes of morbidity and mortality
worldwide, with about 14 million estimated new cases and 8 million
deaths annually.1 For solid tumors such as breast cancer, surgical
removal remains an essential and vital part of the overall treatment
strategy.2 However, the perioperative period is increasingly recognized
as a timepoint with the potential to influence patient outcomes
profoundly.3 First, the mechanical process of tumor resection and
subsequent regenerative processes may promote the recurrence of local
residual disease. Second, perioperative immunosuppression may impair
the host’s ability to attack circulating tumor cells (CTCs) or distant
micrometastases. Third, some drugs administered perioperatively, such as
opioids, have been alleged to promote tumor growth in their own right.3
Therefore, theoretically, regional anesthetic strategies, using local
anesthetics to reversibly block nerve impulse propagation, seem to be
ideally suited to treat perioperative cancer patients. These techniques,
among their other effects, decrease the surgical stress response, preserve
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the patient’s immune system to a greater extent than general anesthesia,
and reduce the need for opioids.4,5 In addition to these indirect effects,
direct cytotoxic effects of local anesthetics on tumor cells as well as
modulation and inhibition of subcellular pathways essential to tumor
progression and metastasis have been described experimentally.6 This
review will thus aim to outline experimental and clinical evidence of how
local anesthetics might be able to interfere with processes important for
the pathogenesis of metastasis during the perioperative period and to
summarize preclinical and clinical evidence supporting their use leading
to a possible better patient outcome.
’ The Clinical Challenge: CTCs-Metastasis
CTCs are released from the primary tumor into the circulation or
the lymphatic system and might then be able to form new metastases.7
The number of CTCs can be correlated with the patient outcome and
has been established as an independent prognostic factor for survival in
metastatic breast, colon, and prostate cancer.8 The concept of CTCs and
their contribution to metastasis and therefore a possible worsened
outcome was first described in 1963 and has gained more and more
attention over the last couple of years.9 Depending on the type of tumor,
the stage of the disease and possible prior treatments (eg, neoadjuvant
chemotherapy), the number of CTCs that can be detected at a given
timepoint during the course of the disease might differ substan-
tially.10–12 However, it has also been demonstrated that there might be
a significant increase in the release of CTCs during the perioperative
period. For example, patients with pancreatic cancer13 might undergo a
successful resection of a primary tumor, but still die from cancer
recurrence due to new metastatic sites formed by the CTCs released
during surgery.14 Therefore, the perioperative period might be crucial
for the individual patient’s outcome and survival.
’ Anti-inflammatory Effects of Local Anesthetics
Potentially Affecting Metastasis
Immune Modulation/Natural Killer (NK) Cell Activity
During surgery, the patient’s body faces a phenomenon called the
“stress response”: the release of several proinflammatory cytokines,
such as interleukins and tumor necrosis factor a (TNFa), leads to a
general proinflammatory state associated with the suppression of
immune cell function.15,16
NK cells, a lymphocytic subset of the innate immune system,17 are
involved in the first line of defense against infected and malignant
cells.18,19 In rats, NK cell activity was significantly attenuated by stress
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and by surgical procedures (laparotomy), which subsequently also led to
an increase in the retention of inoculated tumor cells in these animals.20
In humans undergoing surgery for breast, hepatocellular, or pulmonary
carcinoma, a reduction of NK cell activity has also been observed.21
The influence of anesthetics on NK cell activity has been studied
extensively. The volatile anesthetic halothane, for example, is known to
decrease NK cytolytic activity in rats.22 In addition, this finding was
correlated with a subsequent increase in the retention of intravenously
injected tumor cells in the lungs of the animals, whereas propofol did
not have such an effect.22 Experimental and clinical evidence also points
toward a negative effect of opioids on NK cells, as it has been shown that
morphine significantly depressed the cytolytic activity of these cells in
rats and in healthy volunteers.23,24 This effect could be demonstrated in
cancer patients even after a single dose of morphine (10mg intra-
venously) as early as 30 minutes after the administration of the drug.25
Local anesthetics might only have a detrimental effect on NK cell
activity at very high (and certainly cytotoxic) concentrations in vitro.26 In
contrast, a very recent study showed that lidocaine at clinically relevant
concentrations of 0.01 and 0.1mM was able to enhance NK cytolytic
activity in vitro through the release of lytic granules.27 Similar results
were obtained from a pilot study of patients undergoing breast cancer
resection, who had either received a regional anesthetic (paravertebral
block) in combination with propofol-based total intravenous anesthesia
or intravenous opioids together with a sevoflurane general anesthetic;
serum from women randomized to the regional/total intravenous
anesthesia group induced a greater cytolytic activity in NK cells from
healthy donors than serum from women who had been administered
opioids and sevoflurane,28 indicating a possible beneficial effect of
regional anesthesia and local anesthetics with respect to NK cell activity
in patients undergoing (breast) cancer surgery.
Endothelial Barrier, Leukocyte Activation, Leukocyte/
Tumor Cell Adhesion, and Transmigration
The endothelial barrier plays an important role during the patho-
genesis of metastasis, as the CTCs have to overcome this tight cell wall to
invade the extracellular matrix at remote locations to form new
metastatic sites.29 Because of the surgical stress and the subsequent
release of circulating, proinflammatory cytokines, such as TNFa, during
surgery, endothelial barrier function might also be impaired.30 TNFa
activates nuclear factor kB (NFkB), a key mediator of inflammatory
signaling in leukocytes, endothelial cells, and malignant cells,31 as well as
Src protein tyrosine kinase (Src).31 Src activation, defined as Src
autophosphorylation at tyrosine 419 and dephosphorylation of Src
inhibitory phosphotyrosine 529,32 is known to lead to a massive loss of
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endothelial barrier function and a subsequent increase in vascular
permeability,32 which might enhance the extravasation of CTCs.33 It has
also been shown that this extravasation of malignant cells might depend
on several events which are crucial for the recruitment and the adhesion
of leukocytes to the endothelium and their subsequent transendothelial
migration.33 Intercellular adhesion molecule 1 (ICAM-1), for example,
is not only expressed by endothelial cells,34 but also by several different
types of tumor cells35–38 and is a key component for the adhesion of
leukocytes to the endothelium.39 Once phosphorylated at tyrosine 512
by Src, for example, upon stimulation with TNFa, ICAM-1 binds to
CD11b (integrin aM) on the surface of polymorphonuclear cells (PMN)
(neutrophil granulocytes, PMNs), which then leads to an enhanced
adhesion and subsequent transmigration.34,40 Binding of tumor cell
ICAM-1 to PMN CD11b, might also occur and has been demonstrated
to enhance the extravasation of CTCs significantly.37,41
The anti-inflammatory effects of local anesthetics are well known
and have been studied extensively in vitro, in vivo, and in humans.42,43
For instance, the amide-type local anesthetic ropivacaine was able to
attenuate measures of acute lung injury such as pulmonary edema as
well as neutrophil recruitment and transmigration after the instillation
of bacterial lipopolysaccharide, as surrogates for the integrity of the
endothelial barrier in vivo.44,45 It was also shown that this in vivo
protection might have been due to a decrease in Src and ICAM-1
expression/phosphorylation.45 In vitro, it was demonstrated that
ropivacaine was able to attenuate TNFa-induced signaling events in
endothelial cells by blocking the initiating steps of signal propagation at
the level of TNF receptor-1 right at the cell membrane, thus preserving
endothelial barrier function and attenuating the adhesion of PMNs to
the endothelium.46 In addition, PMN activation and priming are also
attenuated by local anesthetics.47–50 Together with other evidence of
certain protective, anti-inflammatory effects on the endothelium,51,52
these results might indicate a potential beneficial effect of the use of local
anesthetics in patients undergoing cancer surgery, as the extravasation
of CTCs during the perioperative period might be impeded by the
preservation of endothelial barrier function and by a decrease in the
adhesion of leukocytes and cancer cells to the endothelium and their
subsequent transendothelial migration.
Direct Effects on Cancer Cells: Inflammatory Signaling,
Migration, Invasion, Epigenetics
Besides the potentially beneficial effects of the perioperative use of
regional anesthesia and local anesthetics in patients undergoing cancer
surgery due to the preservation of endothelial barrier function46 and a
reduction in opioid consumption,53 several recent studies were also able
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to provide evidence for potential direct effects of local anesthetics on
cancer cells, possibly due to their anti-inflammatory properties. In
addition to its well-described role as a mediator of endothelial
permeability, Src might also be involved in the migration, invasion,
and extravasation of cancer cells.54–56 On stimulation with TNFa, Src
activation and ICAM-1 phosphorylation are increased significantly in
lung adenocarcinoma cells in vitro, a phenomenon that was blocked by
the amide-type local anesthetics lidocaine and ropivacaine, but not by
the ester-type drug chloroprocaine.6 This inhibition seemed to be
independent of the blockade of the voltage-gated sodium channel and
caused a significant decrease in the migratory abilities of the cells.6
Further downstream of Src, the activation of Akt and focal adhesion
kinase could be attenuated by clinically relevant concentrations of both
lidocaine and ropivacaine, leading to a subsequent decrease in the
production of matrix-metalloproteinase 9 (MMP-9) by the cancer cells.57
MMPs are important enzymes for the breakup of the extracellular
matrix during the invasion of cancer cells,58–60 and therefore, the
observed reduction in MMP secretion by the cancer cells after
coincubation of the cells with TNFa and local anesthetics was also
associated with a significant decrease in the invasiveness of the cells.57
Although the described Src-dependent mechanisms might be inde-
pendent of voltage-gated sodium channel blockade, another study also
reported a decreased invasive potential of colon cancer cells in vitro due
to the blocking of the sodium channel variant Nav1.5 by ropivacaine.
61
Apart from the outlined evidence for a potential beneficial effect of
local anesthetics due to their anti-inflammatory properties, the drugs
might also interfere with the regulation of gene expression, also known
as epigenetics, by altering the methylation of DNA of malignant cells.
Current evidence suggests that lidocaine is able to demethylate DNA of
certain breast cancer cell lines at clinically relevant concentrations
in vitro.62 This effect was additive to that of a chemotherapeutic agent
(5-aza-20-deoxycytidine, DAC) and was also observed after incubation
with ropivacaine, but not with bupivacaine.63 Interestingly, this effect is
the opposite compared with long-term opioid intake, which leads to
hypermethylation.64
’ The Relevance of Perioperative Opioid Use in
Cancer Surgery
Both the perioperative and the chronic use of opioids in the setting
of malignancy has been traditionally considered to drive tumor
progression and metastasis,3 and a number of experimental studies
have demonstrated enhanced growth of metastases in models such as
intravenous tumor injection.65 Among other effects, opioids have exper-
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imentally been shown to act as immunosuppressants,66 to increase
angiogenesis,67 and finally to promote metastasis.68 In direct inoculation
models, morphine administration favored tumor progression,65 but
other investigations were not able to replicate this effect.69 However,
many of these models did not mimic a slowly growing tumor, which
metastasizes spontaneously, but rather used artificial inoculation.70 In 1
recent model, which mirrored spontaneous breast cancer metastasis, the
long-term administration of morphine did not lead to an increase in
metastasis.71,72 The same ambivalence can be found in the clinical
literature regarding the clinical effects of morphine on tumor
progression. Although some studies reported an association between
morphine and a worsened tumor-related outcome (shortened
recurrence-free interval, decreased patient survival),73 other studies
did not find similar effects. This might be explained by the
heterogeneity of studies and tumor cell types, and the fact that the
opiate requirement is, through tumor pain, linked to the tumor stage
and progression,74 and may reflect the patient’s general condition more
than playing a major clinical role per se.75
’ Clinical Evidence/Retrospective Analyses
During the last 15 years, several articles have been published dealing
with the effects of regional anesthesia and cancer recurrence. All were
retrospective, and large discrepancies in the results between the
different studies were noted.
Positive Studies
One of the first publications dealing with this topic came from the
Tu¨bingen group: Schlagenhauff and colleagues looked at the type of
anesthesia performed for the excision of primary cutaneous melanoma.
They retrospectively examined the follow-up data of 4329 patients. The
authors found that there was a slight but significantly increased risk of
death for patients treated with general anesthesia as compared with local
anesthesia (no details concerning the procedures were noted).76
In 2006, Exadaktylos et al77 hypothesized that breast cancer patients
undergoing surgery with paravertebral anesthesia and analgesia
combined with general anesthesia would have a better outcome than
those having general anesthesia with postoperative intravenous mor-
phine patient-controlled analgesia. Retrospectively, the authors found
that recurrence and metastasis-free survival was 94% [95% confidence
interval (CI), 87%-100%] and 82% (95% CI, 74%-91%) at 24 months and
94% (95% CI, 87%-100%) and 77% (95% CI, 68%-87%) at 36 months in
the paravertebral and the general anesthesia groups, respectively
(P=0.012).77 Patients in the paravertebral group received a 0.2mL/kg
e22 ’ Piegeler et al
www.anesthesiaclinics.com
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
bolus of 0.25% levobupivacaine before the induction of general
anesthesia, followed by a continuous infusion of 0.25% levobupivacaine
for the first 48 hours postoperatively.
Two years later, another retrospective analysis investigated the
influence of the use of epidural analgesia in patients undergoing radical
prostatectomy for prostate cancer.78 This work showed that the epidural
group had a significantly lower risk of recurrence at 4, 6, 8, and 10 years
after surgery as compared with the group that received general
anesthesia only. In this investigation, the only provided information
regarding the details of the epidural is the duration, which was reported
between 48 and 72 hours postoperatively.
Long-term survival after the resection of colon cancer under general
anesthesia with or without an epidural has subsequently been analyzed
by Christopherson et al.79 Analysis was performed regarding the
presence or the absence of distant metastasis because this had the most
significant effect on survival. The authors found that patients in the
epidural group had an improved survival (P=0.012) before a time
frame of 1.46 years after surgery, whereas later, the type of anesthesia
did not affect survival. Intermittent boluses of 0.5% bupivacaine were
given. The duration of the epidural application was not specified.
Merquiol et al80 retrospectively investigated the effect of cervical
epidural anesthesia in patients undergoing surgery for laryngeal and
hypopharyngeal cancer. Here, the primary outcome was the length of
cancer-free survival. The results showed that the epidural group had
a significantly better cancer-free survival of 68% at 5 years (95% CI,
57%-82%) against 37% (95% CI, 25%-34%) for the control group.
Bupivacaine or ropivacaine were given for 48 hours postoperatively.
The volume and the concentration of LA were not provided.
Another retrospective review of 143 patients undergoing surgery for
ovarian serous adenocarcinoma with or without epidural reported 3-
and 5-year overall survival rates of 78% and 60% in the epidural group
against 58% and 49% in the control group.81 After adjusting for the
other variables, it was found that the control group had a hazard ratio of
1.214 (P=0.04), suggesting a beneficial effect of the epidural in this
setting. The epidural consisted of a continuous infusion of 0.125%
bupivacaine or 0.15% ropivacaine for 48 hours postoperatively. The
volume of LA administered was not specified in this study.
Positive effects of epidural anesthesia on the overall patient survival
after cancer surgery have been shown in 2 meta-analyses, but tumor
recurrence or metastatic disease was not affected.82,83
Negative Studies
Myles and colleagues conducted a follow-up examination of patients
previously enrolled in a randomized controlled clinical trial, the
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multicenter Australian study of Epidural Anesthesia and Analgesia in
Major Surgery, which had not been powered to investigate cancer
recurrence.84 The authors found that the median time to recurrence or
death was 2.8 (95% CI, 0.7-8.7) against 2.6 years (95% CI, 0.7-8.7) in the
epidural group (P=NS). The major drawback of this work is that 50%
of the epidurals apparently did not work, raising serious concerns about
the validity of the results.
The effect of neuraxial anesthesia on the progression of cervical
cancer was retrospectively examined in a small sample of 132
consecutive patients treated with brachytherapy.85 The authors found
that the use of neuraxial anesthesia during the first brachytherapy was
not associated with a reduced risk of local or systemic recurrence
(hazard ratio, 0.95%; 95% CI, 0.54-1.67; P=0.86) or long-term
mortality (hazard ratio, 1.46; 95% CI, 0.81-2.61; P=0.20). No detailed
information regarding the epidural procedure is available from this
study.
Lacassie et al86 conducted a retrospective analysis of patients
undergoing laparotomy for ovarian cancer with or without epidural
analgesia. After propensity score matching, the median time to
recurrence was 1.6 and 1.4 years for the epidural and the control
groups, respectively (P=0.3). No details concerning the epidural
procedure were given.
A large number of patients (>27,000) were retrospectively analyzed
regarding the effects of epidural analgesia against intravenous mor-
phine on survival and cancer recurrence after colectomy.87 The study
revealed recurrence rates of 27.5% and 24.0% in the epidural and the
control groups, respectively. In an adjusted logistic regression analysis,
the incidence of recurrence was comparable in the 2 groups (odds ratio,
1.4; 95% CI, 0.96-2.05). No details concerning the epidural were given.
Mixed Results
Gupta et al88 retrospectively analyzed data of 655 patients who
underwent laparotomy for gastrointestinal cancer with or without an
epidural. Multivariate regression analyses showed that the epidural was
associated with a reduction in all-cause mortality after rectal but not after
colon cancer. The epidural consisted of either a local anesthetic alone or
combined with fentanyl. No other details were provided.
Medical records of 182 patients undergoing surgery for ovarian
cancer with (n=55) or without (n=127) epidural were analyzed
retrospectively.89 This investigation demonstrated that only patients
with an epidural, which had been activated preoperatively, had a
significantly better outcome, whereas patients with postoperative
activation of the epidural had an outcome similar to that of the control
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group with no epidural. No further information dealing with the
epidural procedure was given.
In conclusion, there is a large discrepancy between the outlined
investigations. One has to consider many drawbacks of these works
including the tumor biology, the role of neoadjuvant and other
chemotherapeutic treatments, and concomitant medications. Moreover,
the documentation of the regional anesthetic technique—the key
factor—should always include the concentration, the type, the dosage,
and the duration of application of the local anesthetic. However, in the
majority of the currently available investigations, this information has
been insufficient and/or inadequate, especially in the negative studies.
Without this basic information, no definitive conclusion can be made
from these investigations and further well-designed prospective,
randomized studies are needed.
Currently several randomized controlled trials are recruiting
patients to verify (or disprove) the hypothesis that the perioperative
use of local anesthetics could have an impact on survival or recurrence
after cancer surgery. A recent Cochrane review lists only 4 different
studies with a total of 746 patients,90 including the already mentioned
study by Myles et al.84 The authors concluded that there is currently no
definite evidence for a potential beneficial effect of the perioperative use
of regional anesthesia in cancer patients.90 However, as more results
from randomized controlled trials are published, this might still change.
’ Scenarios of Local Anesthetic Application
In clinical practice, local anesthetics can be applied for infiltration
anesthesia, regional anesthesia (spinal, epidural, and peripheral nerve
blocks), and intravenously in the context of multimodal analgesia.5
During infiltration anesthesia, when a local anesthetic is applied
around the tissue to be excised, millimolar concentrations of local
anesthetics are attained at the site of injection adjacent to the tumor, and
these concentrations have typically been associated with local anesthetic-
induced cell death.91 This might explain the protective effect of local
anesthesia reported for melanoma excision under local anesthesia.76 In
contrast, systemic levels of local anesthetics reached after regional
anesthesia or multimodal analgesia are typically in the low micromolar
range.92 In general, these settings represent the far ends of a spectrum
on the one end of which lower micromolar concentrations are associated
with the modulation of subcellular pathways, whereas on the other end
at millimolar concentrations, direct cytotoxicity is observed.46,62,93
Whether perioperative regional anesthesia is indeed found to decrease
tumor recurrence at least in some models,4 the next major question to be
addressed would be which exact component of regional anesthesia might
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be responsible for this effect. Approximately 1 decade after the first major
clinical trial demonstrating clinical benefits of intravenous lidocaine in
visceral surgery patients,43 we have come to realize that high-volume
plexus blocks and epidural anesthesia are followed by the absorption of
the local anesthetic into the systemic circulation, and that these local
anesthetics are responsible for a substantial share of the beneficial effects of
regional anesthesia, such as anti-inflammation and antihypercoagulability.5
These latter effects might also be of relevance in tumor surgery. The
intravenous application of lidocaine has been demonstrated firmly to have
a beneficial effect after visceral surgery when considering acute outcome
parameters such as the length of stay and the recovery of bowel function.94
However, direct comparisons suggest that the efficacy of epidural
anesthesia to attenuate the surgical stress response is superior to that of
systemic local anesthetics alone.95 The question of whether any potential
antitumor effect of local anesthetics can be elicited by the intravenous
administration of local anesthetics or whether it might be necessary to
administer both (epidural or peripheral) nerve block and attain systemic
levels in the bargain, remains to be defined.
’ Implications for Daily Practice and Outlook
The relevance of amide-type local anesthetics in the perioperative
setting of tumor surgery is still debated, and there is currently no
evidence to suggest that regional anesthesia techniques or intravenous
local anesthetics should be considered as mandatory components for a
comprehensive perioperative anesthesia plan for these patients.
However, there may be other good reasons to administer intravenous
local anesthetics with or without regional anesthesia in patients under-
going cancer surgery. First, taking visceral surgery as a prototype, 2 recent
meta-analyses demonstrated an improved overall survival when perioper-
ative epidural anesthesia was used, although no difference in oncological
parameters was observed.82,83 Second, the incidence of chronic pain may
be influenced by the type of analgesia. In particular, after thoracotomy and
mastectomy, the incidence of chronic postsurgical pain is decreased when
epidural or paravertebral blockade is performed.96 A similar effect was
noted after the combination of epidural and ketamine analgesia for
laparotomy.97 Therefore, the choice of regional technique, at the moment,
should be based on the planned surgical procedure and on the individual
patient, rather than on the specific malignancy.
’ Conclusions
The role of amide local anesthetics, whether administered for
infiltration, regional anesthesia or intravenously, in the perioperative
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care of tumor patients is still unclear. A substantial body of theoretical
and experimental evidence suggests that by both direct and indirect
effects, local anesthetics might be beneficial for the treatment of cancer
patients. Clinical evidence still largely depends on underpowered and/or
retrospective studies, and to date, the enthusiastic results from some
animal trials have not been replicated in clinical practice. Adding to the
complexity, the sheer biological diversity of human tumors, the array of
local anesthetics available and their different routes of administration, as
well as patient-specific considerations will most likely preclude a single
and universal answer to the question of whether local anesthetics might
have the potential to help reduce metastases. Currently, the choice to
institute local, regional, or intravenous local anesthetics should be based
on the surgical procedure and the patient status, and cannot be
mandated on the basis of oncologic grounds.
The authors declare that they have nothing to disclose.
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